Skip to content

Study · Randomized controlled trial · 2024

8 results

Continuous Positive Airway Pressure but Not GLP1-mediated Weight Loss Improves Early Cardiovascular Disease in Obstructive Sleep Apnea: A Randomized Proof-of-Concept Study.

O'Donnell C, Crilly S, O'Mahony A, O'Riordan B, Traynor M, Gitau R, McDonald K, Ledwidge M, O'Shea D, Murphy DJ, Dodd JD, Ryan S

Annals of the American Thoracic Society1 Mar 2024Cited by 53 (Europe PMC)

PMID38096106 (opens in a new tab)DOI10.1513/annalsats.202309-821oc (opens in a new tab)PepBankPUB-38096106
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with obstructive sleep apnea, liraglutide alone gave a smaller reduction in apnea-hypopnea index (mean difference -12 events/h) than CPAP alone or the combination.

    In plain wordsIn people with sleep apnea, liraglutide alone reduced breathing interruptions less than CPAP alone or the combination did.

    Peptide
    Liraglutide
    Outcome
    DecreaseApnea-hypopnea index (liraglutide alone)
    Study

    n: not reported in source

    Comparator
    CPAP alone and CPAP plus liraglutide
    Outcome group
    Sleep · Respiratory
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Mean difference in AHI
    −12 events/h
    liraglutide alone

    Source sentences

    Summary
    CPAP alone and in combination resulted in greater reduction in apnea-hypopnea index than Lir alone (mean difference, -45 and -43 events/h, respectively, vs. -12 events/h; P < 0.05).
    1 context sentence
    Summary · context
    We performed a randomized proof-of-concept study comparing CPAP, a GLP1-mediated weight-loss regimen (liraglutide [Lir]), and both in combination for 24 weeks in 30 consecutive patients with OSA (apnea-hypopnea index >15 events/h; body mass index 30-40 kg/m2; and no history of diabetes, h…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with obstructive sleep apnea, liraglutide alone led to significant weight loss.

    In plain wordsIn people with sleep apnea, liraglutide alone led to significant weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight (liraglutide alone)
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Both Lir and combination treatment led to significant weight loss, but only CPAP alone resulted in significant decrease in vascular inflammation (aortic wall target-to-background ratio from 2.03 ± 0.34 to 1.84 ± 0.43; P = 0.010), associated with an improvement in endothelial function and a de…
    1 context sentence
    Summary · context
    We performed a randomized proof-of-concept study comparing CPAP, a GLP1-mediated weight-loss regimen (liraglutide [Lir]), and both in combination for 24 weeks in 30 consecutive patients with OSA (apnea-hypopnea index >15 events/h; body mass index 30-40 kg/m2; and no history of diabetes, h…
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with obstructive sleep apnea, liraglutide alone did not significantly decrease aortic wall vascular inflammation; only CPAP alone did.

    In plain wordsIn people with sleep apnea, liraglutide alone did not significantly reduce inflammation in the aortic wall; only CPAP alone did.

    Peptide
    Liraglutide
    Outcome
    No significant changeAortic wall vascular inflammation (liraglutide alone)
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    but only CPAP alone resulted in significant decrease in vascular inflammation (aortic wall target-to-background ratio from 2.03 ± 0.34 to 1.84 ± 0.43; P = 0.010), associated with an improvement in endothelial function and a decrease in C-reactive protein.
    1 context sentence
    Summary · context
    We performed a randomized proof-of-concept study comparing CPAP, a GLP1-mediated weight-loss regimen (liraglutide [Lir]), and both in combination for 24 weeks in 30 consecutive patients with OSA (apnea-hypopnea index >15 events/h; body mass index 30-40 kg/m2; and no history of diabetes, h…
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with obstructive sleep apnea, low-attenuation coronary plaque volume did not decrease with liraglutide alone, but decreased with CPAP and with combination therapy.

    In plain wordsIn people with sleep apnea, unstable coronary plaque volume did not fall with liraglutide alone, but fell with CPAP and with the combination.

    Peptide
    Liraglutide
    Outcome
    No significant changeLow-attenuation coronary plaque volume (liraglutide alone)
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Low-attenuation coronary artery plaque volume as a marker of unstable plaque also decreased with CPAP (from 571 ± 490 to 334 ± 185 mm3) and with combination therapy (from 401 ± 145 to 278 ± 126 mm3) but not with Lir.
    1 context sentence
    Summary · context
    We performed a randomized proof-of-concept study comparing CPAP, a GLP1-mediated weight-loss regimen (liraglutide [Lir]), and both in combination for 24 weeks in 30 consecutive patients with OSA (apnea-hypopnea index >15 events/h; body mass index 30-40 kg/m2; and no history of diabetes, h…

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In patients with obstructive sleep apnea, CPAP plus liraglutide gave a greater reduction in apnea-hypopnea index (mean difference -43 events/h) than liraglutide alone.

    In plain wordsIn people with sleep apnea, CPAP plus liraglutide reduced breathing interruptions more than liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseApnea-hypopnea index (CPAP plus liraglutide)
    Study

    n: not reported in source

    Comparator
    Liraglutide alone
    Outcome group
    Sleep · Respiratory

    Measurements

    Mean difference in AHI
    −43 events/h
    CPAP plus liraglutide

    Source sentences

    Summary
    CPAP alone and in combination resulted in greater reduction in apnea-hypopnea index than Lir alone (mean difference, -45 and -43 events/h, respectively, vs. -12 events/h; P < 0.05).
    1 context sentence
    Summary · context
    We performed a randomized proof-of-concept study comparing CPAP, a GLP1-mediated weight-loss regimen (liraglutide [Lir]), and both in combination for 24 weeks in 30 consecutive patients with OSA (apnea-hypopnea index >15 events/h; body mass index 30-40 kg/m2; and no history of diabetes, h…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In patients with obstructive sleep apnea, CPAP plus liraglutide led to significant weight loss.

    In plain wordsIn people with sleep apnea, CPAP plus liraglutide led to significant weight loss.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight (CPAP plus liraglutide)
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Both Lir and combination treatment led to significant weight loss, but only CPAP alone resulted in significant decrease in vascular inflammation (aortic wall target-to-background ratio from 2.03 ± 0.34 to 1.84 ± 0.43; P = 0.010), associated with an improvement in endothelial function and a de…
    1 context sentence
    Summary · context
    We performed a randomized proof-of-concept study comparing CPAP, a GLP1-mediated weight-loss regimen (liraglutide [Lir]), and both in combination for 24 weeks in 30 consecutive patients with OSA (apnea-hypopnea index >15 events/h; body mass index 30-40 kg/m2; and no history of diabetes, h…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In patients with obstructive sleep apnea, CPAP plus liraglutide did not significantly decrease aortic wall vascular inflammation; only CPAP alone did.

    In plain wordsIn people with sleep apnea, CPAP plus liraglutide did not significantly reduce inflammation in the aortic wall; only CPAP alone did.

    Peptide
    Liraglutide
    Outcome
    No significant changeAortic wall vascular inflammation (CPAP plus liraglutide)
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Cardiovascular

    Source sentences

    Summary
    but only CPAP alone resulted in significant decrease in vascular inflammation (aortic wall target-to-background ratio from 2.03 ± 0.34 to 1.84 ± 0.43; P = 0.010), associated with an improvement in endothelial function and a decrease in C-reactive protein.
    1 context sentence
    Summary · context
    We performed a randomized proof-of-concept study comparing CPAP, a GLP1-mediated weight-loss regimen (liraglutide [Lir]), and both in combination for 24 weeks in 30 consecutive patients with OSA (apnea-hypopnea index >15 events/h; body mass index 30-40 kg/m2; and no history of diabetes, h…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 08HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In patients with obstructive sleep apnea, low-attenuation coronary plaque volume decreased with CPAP plus liraglutide (from 401 to 278 mm3).

    In plain wordsIn people with sleep apnea, unstable coronary plaque volume fell with CPAP plus liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseLow-attenuation coronary plaque volume (CPAP plus liraglutide)
    Study

    n: not reported in source

    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Plaque volume before
    401 mm3
    CPAP plus liraglutide
    Plaque volume after
    278 mm3
    CPAP plus liraglutide

    Source sentences

    Summary
    Low-attenuation coronary artery plaque volume as a marker of unstable plaque also decreased with CPAP (from 571 ± 490 to 334 ± 185 mm3) and with combination therapy (from 401 ± 145 to 278 ± 126 mm3) but not with Lir.
    1 context sentence
    Summary · context
    We performed a randomized proof-of-concept study comparing CPAP, a GLP1-mediated weight-loss regimen (liraglutide [Lir]), and both in combination for 24 weeks in 30 consecutive patients with OSA (apnea-hypopnea index >15 events/h; body mass index 30-40 kg/m2; and no history of diabetes, h…

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT04186494

Effect of Liraglutide vs CPAP on Cardiometabolic Outcomes in Obstructive Sleep Apnea

St Vincent's University Hospital, Irelandn = 302 Dec 2019 to 31 Jul 2022

Sleep Apnea, Obstructive

Trial pageClinicalTrials.govUpdated 18 Dec 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.